From insulin therapies and GLP-1 receptor agonists to cutting-edge oral anti-diabetic drugs, the growing range of available treatments is leading to more personalized and effective solutions for patients
This patient-centered approach means were not only managing diabetes but actively preventing long-term complications, which is a huge step forward in improving outcomes
"NPS, PEDs and other emerging drugs on the Clearnet and the Darkweb: Use in sport"
Altogether, these converging findings highlight the hybrid potential of exercise, GLP-1based therapies, and neuromodulation to optimize weight management, cognitive function, and metabolic health
This is a bit misleading as it looks like the price of the medication is $49
The FIDELIO-DKD trial was the first study specifically designed to evaluate the long-term effects of finerenone on kidney and cardiovascular outcomes ( Complementing the findings of the FIDELIO-DKD trial, the FIGARO-DKD study further evaluated the efficacy and safety of finerenone, with a primary focus on cardiovascular outcomes in patients with CKD and T2DM ( P = 0.03)